Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 3
1(25.0%)
4Total
N/A(3)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05472285Not ApplicableCompleted

Evaluation of the Effects of a Food Supplementation on the Improvement of Cognitive Functions in Healthy Seniors

Role: lead

NCT02880657Not ApplicableUnknown

Evaluation of SODB® (Superoxide Dismutase by Bionov®) in the Physical Condition Improvement in Healthy Subjects

Role: lead

NCT02667691Not ApplicableUnknown

Evaluation of SODB® in Metabolic Adaptations in Overweight Women

Role: lead

NCT01767922Phase 3Completed

Multicentre, Double-blind Study Versus Placebo on Impact and Safety of Extramel® 140 IU on Perceived Stress, Physical and Intellectual Fatigue, Pain Perception if Present, and the Impact on the Quality of Life

Role: lead

All 4 trials loaded